New hope for colorectal cancer: Chemo-Free cocktail shows promise in early trial
NCT ID NCT07257653
First seen Dec 04, 2025 · Last updated Apr 24, 2026 · Updated 21 times
Summary
This study tests whether combining two targeted drugs (cetuximab beta and fruquintinib) with or without immunotherapy can control advanced colorectal cancer without chemotherapy. About 70 people with a specific genetic type (RAS/BRAF wild-type) will receive the treatment as their first therapy. The goal is to see if this approach delays cancer growth and is safe enough to avoid harsh chemo side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Second Affiliated Hospital Zhejiang University College of Medicine, Hangzhou, Zhejiang Province 310999
RECRUITINGHangzhou, Zhejiang, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.